MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 18, 2004; DOI: 10.1124/mol.104.005801


0026-895X/05/6703-815-826$20.00
Mol Pharmacol 67:815-826, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.005801v1
67/3/815    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bladh, L.-G.
Right arrow Articles by Okret, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bladh, L.-G.
Right arrow Articles by Okret, S.
ORIGINAL ARTICLE

Identification of Endogenous Glucocorticoid Repressed Genes Differentially Regulated by a Glucocorticoid Receptor Mutant Able to Separate between Nuclear Factor-{kappa}B and Activator Protein-1 Repression

Lars-Göran Bladh, Johan Lidén, Karin Dahlman-Wright, Mark Reimers1, Stefan Nilsson, and Sam Okret

Departments of Medical Nutrition (L.-G.B., S.O.) and Biosciences (J.L., K.D-W., M.R.), Karolinska Institutet and Karo Bio AB, Novum, Huddinge, Sweden (S.N.)

Abstract

Glucocorticoids are commonly used in the clinic, but long-term treatment is often associated with severe side effects. One way to reduce unwanted effects is to restrict glucocorticoid receptor (GR) signaling through defined pathways. In this study, we examine endogenous target genes regulated by a GR mutant that in contrast to the wild-type GR is unable to repress stimulated nuclear factor-{kappa}B (NF-{kappa}B) activity, whereas repression of activator protein-1 (AP-1) activity is maintained. This GR mutant (GRR488Q) harbors a point mutation in the second zinc finger of the DNA binding domain. Its ability to distinguish between NF-{kappa}B and AP-1 repression is defined using reporter genes regulated by both simple and natural promoters. The inability of GRR488Q to repress NF-{kappa}B was not related to its inability to activate target genes through a glucocorticoid response element. Furthermore, the discriminating property was observed in three different cell lines, suggesting that this is not a cell-specific effect. These results show that different receptor surfaces or mechanisms are involved in repression of NF-{kappa}B and AP-1, respectively. It is interesting that the GRR488Q still interacted physically with NF-{kappa}B. Gene expression profiling of human embryonic kidney 293 cells, which express the wild-type GR and the GRR488Q mutant allowed identification of endogenous genes preferentially repressed by GR interference with NF-{kappa}B activity. The genes differentially regulated by GRR488Q mutant versus the wild-type GR after 2 h of treatment seem mainly to be involved in control of transcription and cell growth. At 8 h, no such distinction could be seen.


Received August 26, 2004; accepted November 17, 2004

Address correspondence to: Dr. Sam Okret, Department of Medical Nutrition, Karolinska Institutet, Karolinska University Hospital in Huddinge, Novum, SE-141 86 Huddinge, Sweden. E-mail: sam.okret{at}mednut.ki.se




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
X. Wang, Y. Li, X. Zhu, Y. Wang, F. Diao, and J. Lu
Signal regulatory protein {alpha}1 is involved in the inhibitory effect of glucocorticoid receptor on the proliferation of murine macrophage RAW264.7 cell and mouse peritoneal macrophage
J. Mol. Endocrinol., November 1, 2008; 41(5): 393 - 403.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
K. Johansson-Haque, E. Palanichamy, and S. Okret
Stimulation of MAPK-phosphatase 1 gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP
J. Mol. Endocrinol., October 1, 2008; 41(4): 239 - 249.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Sharma and A. Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors
Blood, August 15, 2008; 112(4): 1338 - 1345.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Mao, A. K. Stewart, R. Hurren, A. Datti, X. Zhu, Y. Zhu, C. Shi, K. Lee, R. Tiedemann, Y. Eberhard, et al.
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin
Blood, December 1, 2007; 110(12): 4047 - 4054.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Newton and N. S. Holden
Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor?
Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. Rhen and J. A. Cidlowski
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.
N. Engl. J. Med., October 20, 2005; 353(16): 1711 - 1723.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics